Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Safety warnings

Diarrhoea treatment associated with serious heart problems

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned of serious cardiac adverse reactions in patients misusing or abusing loperamide by taking high or very high doses of the drug.

Loperamide, which is sold under the brand name Imodium as well as in generic form, is a synthetic opioid indicated for treatment of acute diarrhoea. The MHRA said that a European review identified 19 cases worldwide suggestive of cardiac rhythm disorders associated with loperamide abuse or misuse: in self-treatment of opioid withdrawal, for example. 

As a consequence, the MHRA said pharmacists should remind patients not to take more than the recommended dose on the label, and should report all suspected adverse reactions, including those associated with abuse or misuse, to the Yellow Card Scheme.

The Pharmacovigilance Risk Assessment Committee, the European Medicines Agency’s committee responsible for assessing and monitoring the safety of human medicines, has asked all manufacturers of loperamide products to update their product information with warnings of cardiac events associated with high doses. Patient information leaflets will also be updated with warnings that patients must never take more than the recommended amount of the drug.

Full details of the alert are available on the MHRA website.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20203659

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • MHRA building

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.